www.perpetualcommotion.com
"Give with a free hand, but give only your own."
-- J.R.R. Tolkien The Children of Hurin
- Vitamin D -
General Information:
Names:
Wikipedia entry:
Dr. Ray Shahelien entry:
********************************************************************************************
Observations:
Vitamin
D3
See also Curcumin
Recommendation
from The Vitamin D Council
Here
is a new study that claims to clear Beta Amyloid plaques by
combining vitamin D3 and a bio-available, possibly synthetic,
curcumin.
Vitamin D, Curcumin May Help Clear Amyloid Plaques
Found In Alzheimer's Disease
ScienceDaily
(July 16, 2009) — UCLA scientists and colleagues from UC
Riverside and the Human BioMolecular Research Institute have
found that a form of vitamin D, together with a chemical found
in turmeric spice called curcumin, may help stimulate the immune
system to clear the brain of amyloid beta, which forms the
plaques considered the hallmark of Alzheimer's disease...
http://www.sciencedaily.com/releases/2009/07/090715131558.htm
Vitamin D, curcumin may help clear
amyloid plaques found in Alzheimer's
UCLA Newsroom
Early research findings
may lead to new treatments for the disease
By Rachel Champeau July
15, 2009 Category: Health Sciences, Research
UCLA scientists and
colleagues from UC Riverside and the Human BioMolecular Research
Institute have found that a form of vitamin D, together with a
chemical found in turmeric spice called curcumin, may help
stimulate the immune system to clear the brain of amyloid beta,
which forms the plaques considered the hallmark of Alzheimer's
disease.
The early research
findings, which appear in the July issue of the Journal of
Alzheimer's Disease, may lead to new approaches in preventing
and treating Alzheimer's by utilizing the property of vitamin D3
— a form of vitamin D — both alone and together with natural or
synthetic curcumin to boost the immune system in protecting the
brain against amyloid beta...
http://newsroom.ucla.edu/portal/ucla/ucla-study-finds-vitamin-d-may-94903.aspx
Higher vitamin D linked to better
physical functioning in elderly
by Neha Jindal - April 27,
2010
In a notable study,
researchers claim to have found that higher blood levels of
vitamin D improve physical functioning in the elderly.
Researchers
at Wake Forest University in Winston-Salem, U.S., established
that high levels of vitamin D not only help battle cold, cancer,
diabetes and heart diseases but also perk up physical activity
in the aged.
Lead researcher and
assistant professor, internal medicine, Wake Forest University,
Denise Houston, PhD, RD, was quoted by WebMD as saying, “Those
with better vitamin D levels started out better and ended up
better on physical performance tests.”
http://www.themedguru.com/20100427/newsfeature/higher-vitamin-d-linked-better-physical-functioning-elderly-86134554.html
Low Vitamin D Level Tied to Cognitive Decline
Study Shows Elderly People
With Higher Vitamin D Levels Performed Better on Mental Tests
By Charlene Laino
WebMD Health News
Reviewed by Louise Chang,
MD
April 16, 2010 (Toronto)
-- Two new studies add to evidence that older people with low
levels of vitamin D may be more likely to suffer from cognitive
impairment.
The hope is that vitamin D
supplements may be able to slow mental decline -- an
intervention that one research team plans to put to the test
this summer.
Vitamin D is best known
for helping the body absorb calcium, which restores and
strengthens bone, protecting against fracture.
But vitamin D also seems
to have anti-inflammatory effects that may help keep blood
vessels healthy, ensuring nutrient- and oxygen-rich blood flow
to brain cells, says Amie Peterson, MD, of Oregon Health &
Science University in Portland.
In addition, the presence
of vitamin D receptors throughout the brain suggests that it may
directly affect brain tissue, she tells WebMD.
http://www.webmd.com/healthy-aging/news/20100416/low-vitamin-d-level-tied-to-cognitive-decline
Do Vitamin D Deficiency and
Cognitive Decline Go Hand‐in‐Hand?
Neurology Today
7 January 2010; Volume
10(1); p 10
FALLIK, DAWN
Two independent research
groups showed a connection between vitamin D deficiency and
cognitive decline in cross-sectional studies, while the third
found no statistically significant association in a longitudinal
study.
While vitamin D has long
been known to assist calcium absorption in the body,
investigators have begun to explore, as well, its role in
supporting cognitive function and preventing dementia.
But exactly what that role
is requires further research, according to the lead
investigators of three studies published online Nov. 25 ahead of
the Jan. 5 print edition of Neurology. Two independent research
groups showed a connection between vitamin D deficiency and
cognitive decline in cross-sectional studies, while the third
found no statistically significant association in a longitudinal
study.
Although the findings were
inconclusive, the investigators agreed on this point: Clinicians
need to be careful in prescribing supplements, because it is
unclear what dose, if any, is most effective. And they warned
patients not to consider vitamin D a “wonder drug,” because,
unlike vitamin C excess, which the body eliminates, vitamin D is
stored in fat, and an overdose can cause problems...
http://www.aan.com/elibrary/neurologytoday/?event=home.showArticle&id=ovid.com:/bib/ovftdb/00132985-201001070-00007
Originally posted November 19, 2009 12:16 PM to the Alz.org
"Curcumin clinical trial" thread on the Medications/Treatments
for Alzheimer's and Other Related Dementias discussion
forum:
"...Another
study has found that stimulation of scavenger cells
(macrophages) by the vitamin D derivative 1,25 hydroxyvitamin D
(which is the hormonally active form of the vitamin), in
combination with compounds called curcuminoids, also have
effects on macrophages which may result in removal of the
offending substances and structures. Vitamin D is known to have
beneficial effects on immunity, and cucurmin (from turmeric) has
been shown before to have beneficial properties..."
Sources:
Masoumi A, et al. J Alzheimers Disease 2009;17:703–17.
http://www.everybody.co.nz/page-8cbc924f-812b-4ba5-8ffa-ad7e42580d64.aspx
It seems rather intriguing. No, I don't understand it completely
but it seems that some form of vitamin D increases the
effectiveness of curcuminoids.
Here is the abstract of the cited paper:
1α,25-dihydroxyvitamin
D_{3} Interacts with Curcuminoids to Stimulate Amyloid-β
Clearance by Macrophages of Alzheimer's Disease Patients
Journal of Alzheimer's
Disease
Publisher
IOS Press
ISSN 1387-2877 (Print)
1875-8908 (Online)
Issue Volume 17, Number 3
/ 2009
DOI 10.3233/JAD-2009-1080
Pages 703-717
Authors
Ava Masoumi1, Ben
Goldenson1, Senait Ghirmai2, Hripsime Avagyan1, Justin Zaghi1,
Ken Abel2, Xueying Zheng2, Araceli Espinosa-Jeffrey3, Michelle
Mahanian1, Phillip T. Liu4, Martin Hewison1, Matthew Mizwicki5,
John Cashman2, Milan Fiala1
Abstract
Patients
with Alzheimer's disease (AD) suffer from brain amyloidosis
related to defective clearance of amyloid-β (Aβ) by the innate
immune system. To improve the innate immune system of AD
patients, we studied immune stimulation of macrophages by
1α,25(OH)_{2}-vitamin D_{3}(1,25D3) in combination with
curcuminoids. AD patients' macrophages segregate into Type I
(positively stimulated by curcuminoids regarding MGAT-III
transcription) and Type II (not stimulated). In both Type I and
Type II macrophages, 1,25D3 strongly stimulated Aβ phagocytosis
and clearance while protecting against apoptosis. Certain
synthetic curcuminoids in combination with 1,25D3 had additive
effects on phagocytosis in Type I but not Type II macrophages.
In addition, we investigated the mechanisms of 1,25D3 and
curcuminoids in macrophages. The 1,25D3 genomic antagonist
analog MK inhibited 1,25D3 but not curcuminoid effects,
suggesting that 1,25D3 acts through the genomic pathway. In
silico, 1,25D3 showed preferential binding to the genomic pocket
of the vitamin D receptor, whereas bisdemethoxycurcumin showed
preference for the non-genomic pocket. 1,25D3 is a promising
hormone for AD immunoprophylaxis because in Type I macrophages
combined treatment with 1,25D3 and curcuminoids has additive
effects, and in Type II macrophages 1,25D3 treatment is
effective alone. Human macrophages are a new paradigm for
testing immune therapies for AD.
http://iospress.metapress.com/content/k457101686r62685/?p=299e6f877b2848309f40294ee2a89c52&pi=20
http://alzheimers.infopop.cc/eve/forums/a/tpc/f/762104261/m/834108421?r=195102752#195102752
Originally posted January 16, 2010 09:17 AM to the Alz.org
"Curcumin clinical trial" thread on the Medications/Treatments
for Alzheimer's and Other Related Dementias discussion
forum:
While re-reading the older posts in this tread, I saw a message I
posted back on November 19 about vitamin D that I completely
forgot about.
If I'm reading the articles correctly, it seems that Vitamin D
helps the body use curcumin more effectively to remove the amyloid
beta plaques.
The wording of the abstract makes it sound like they used some
exotic form of Vitamin D, but according to Wikipedia, Vitamin D is
converted to this "1,25 hydroxyvitamin D".
"After
vitamin D is produced in the middle layers of skin or consumed
in food, it is converted in the liver and kidney to form 1,25
dihydroxyvitamin D, (1,25(OH)2D), the physiologically active
form of vitamin D (when "D" is used without a subscript it
refers to either D2 or D3). This physiologically active form of
vitamin D is known as calcitriol. Following this conversion,
calcitriol is released into the circulation, and by binding to a
carrier protein in the plasma, vitamin D binding protein (VDBP),
it is transported to various target organs."
http://en.wikipedia.org/wiki/Vitamin_D
http://alzheimers.infopop.cc/eve/forums/a/tpc/f/762104261/m/834108421?r=512106603#512106603
Amyloid-beta transporter
expression at the blood-CSF barrier is age-dependent.
Pascale CL, Miller MC,
Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, Johanson CE,
Silverberg GD.
Fluids Barriers CNS. 2011
Jul 8;8(1):21.
Abstract
ABSTRACT: BACKGROUND: Age
is the major risk factor for many neurodegenerative diseases,
including Alzheimer's disease (AD). There is an accumulation of
amyloid-beta peptides (Abeta) in both the AD brain and the
normal aging brain. Clearance of Abeta from the brain occurs via
active transport at the blood-brain barrier (BBB) and
blood-cerebrospinal fluid barrier (BCSFB). With increasing age,
the expression of the Abeta efflux transporters is decreased and
the Abeta influx transporter expression is increased at the BBB,
adding to the amyloid burden in the brain. Expression of the
Abeta transporters at the choroid plexus (CP) epithelium as a
function of aging was the subject of this study. Methods: This
project investigated the changes in expression of the Abeta
transporters, the low density lipoprotein receptor-related
protein-1 (LRP-1), P-glycoprotein (P-gp), LRP-2 (megalin) and
the receptor for advanced glycation end-products (RAGE) at the
BCSFB in Brown-Norway/Fischer rats at ages 3, 6, 9, 12, 20, 30
and 36 months, using real time RT-PCR to measure transporter
mRNA expression, and immunohistochemistry (IHC) to measure
transporter protein on isolated rat CP. For both the RT-PCR and
the IHC analyses a single-factor ANOVA followed by Tukey's
pairwise comparisons were used to analyze the data. Results:
There was an increase in the transcription of the Abeta efflux
transporters, LRP-1 and P-gp, no change in RAGE expression and a
decrease in LRP-2, the CP epithelium influx transporter, at the
BCSFB with aging. Decreased Abeta42 concentration in the CP, as
measured by quantitative IHC, was associated with these Abeta
transporter alterations. Conclusions: Age-dependent alterations
in the CP Abeta transporters are associated with a decrease in
Abeta42 accumulation in the CP, and are reciprocal to the
changes seen in these transporters at the BBB, suggesting a
possible compensatory role for the BCSFB in Abeta clearance in
aging.
PMID:21740544 [PubMed]
http://www.ncbi.nlm.nih.gov/pubmed/21740544
Free Full Text: http://www.fluidsbarrierscns.com/content/8/1/21/abstract
The following article is from The Vitamin D Council:
Dietary vitamin D intake and sun
exposure linked to lower risk of Alzheimer’s in France
Posted on April 23, 2012
by Dr. William Grant
A paper published ahead of
print on April 13 found that consumption of vitamin D-rich foods
and midday sun exposure were associated with significantly
reduced risk of developing Alzheimer’s disease [Annweiler et
al., 2012]. The study was an add-on to the Epidemiology of
Osteoporosis (EPIDOS) Toulouse cohort study at 43.6º N.
Higher vitamin D dietary intake is associated with
lower risk of Alzheimer’s disease: A 7-year follow-up.
Annweiler C, et al.
J Gerontol A Biol
Sci Med Sci. 2012 Apr 13.
This cohort included women
over the age of 75 years at time of enrollment and was designed
to study risk factors for hip fractures over a four-year period.
Women who had taken vitamin D supplements in the 18 months prior
to enrollment were excluded. Dietary factors and midday sun
exposure habits were examined at time of enrollment. The mean
dietary vitamin D intake was 334±172 IU/day. The presence of
Alzheimer’s disease and other dementias was assessed seven years
after enrollment.
Those in the highest fifth
of vitamin D intake had one-quarter the incidence rate of
Alzheimer’s disease as the other four fifths [odds ratio (OR) =
0.23 (95% confidence interval (CI), 0.08-0.69)]. In addition,
those in the highest fifth of sun exposure had half the
incidence rate of Alzheimer’s disease [OR = 0.45 (95% CI,
0.24-0.85)]. Neither dietary vitamin D intake nor sun exposure
was significantly associated with risk of other dementia.
As mentioned in the paper,
there is a considerable body of literature reporting that fish
consumption is associated with reduced risk of Alzheimer’s
disease, with the usual reason given that fish is an important
dietary source of omega-3 fatty acids. This finding was likely
first reported in an ecological study in 1997 [Grant, 1997].
Thus, it is not clear from the present study how much of the
reduced risk of Alzheimer’s disease was due to omega-3 fatty
acids and how much to vitamin D.
However, the finding
regarding sun exposure at midday strongly supports the role of
vitamin D in reducing risk. Casual sun exposure in England for
those aged 45 years is sufficient to increase serum
25-hydroxyvitamin D concentrations by 38 nmol/l (15 ng/ml)
[Hyppönen and Power, 2007]. This increase is equivalent to about
1500-2000 IU/day [Garland, 2011]. However, for those over the
age of 75 years, vitamin D production rates would be less,
perhaps one-half as much [MacLaughlin and Holick, 1985].
Thus, this study provides
good evidence that fish consumption and midday sun exposure
reduce the risk of Alzheimer’s disease, with vitamin D being the
likely agent. The neuroprotective actions of vitamin D are
discussed in the paper by Annweiler et al.
References
Annweiler C, Rolland Y,
Schott AM, Blain H, Vellas B, Herrmann FR, Beauchet O. Higher
vitamin D dietary intake is associated with lower risk of
Alzheimer’s disease: A 7-year follow-up. J Gerontol A Biol Sci
Med Sci. 2012 Apr 13. [Epub ahead of print]
Garland CF, French CB,
Baggerly LL, Heaney RP. Vitamin D supplement doses and serum
25-hydroxyvitamin D in the range associated with cancer
prevention. Anticancer Res 2011:31: 617-22.
Grant WB. Dietary links to
Alzheimer’s disease. Alz Dis Rev 1997;2:42-55.
(http://www.sunarc.org/JAD97.pdf)
Hyppönen E, Power C.
Hypovitaminosis D in British adults at age 45 y: nationwide
cohort study of dietary and lifestyle predictors. Am J Clin
Nutr. 2007 Mar;85(3):860-8.
MacLaughlin J, Holick MF.
Aging decreases the capacity of human skin to produce vitamin
D3. J Clin Invest. 1985 Oct;76(4):1536-8.
- PMID:
22503994 [PubMed]
- http://www.ncbi.nlm.nih.gov/pubmed/22503994
- http://blog.vitamindcouncil.org/2012/04/23/dietary-vitamin-d-intake-and-sun-exposure-linked-to-lower-risk-of-alzheimers-in-france/
Reuters, 7.5.12 A new analysis of nearly
a dozen studies testing vitamin D in older individuals has
concluded that it takes a daily dose of at least 800 international
units (IU) to consistently prevent broken bones. A dose that high
was found to reduce the risk of hip fracture by 30 percent and
other breaks by 14 percent. Lower doses didn’t have any effect.
The report, published in the New England Journal of Medicine, also
suggests that too much calcium -- perhaps more than 1,000
milligrams (mg) per day -- can weaken the benefit.
[NEED LINK]
********************************************************************************************
Known sources:
********************************************************************************************
Natural sources:
********************************************************************************************
References:
********************************************************************************************
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Home Preface
Brain Failure Notes References
pg. 1 References pg. 2
Nutritional Alternatives
Patricia's Protocol Tauopathy
Discussion
Forum
Correspondence Newsletters Poems Memory Enhancement
Click to
join tauopathies
********************************************************************************************
Questions or
comments, contact "perpetualcommotion.com" at gmail.com
Updated: July
2, 2012
Inception: July 2, 2012